MEDIPHARM LABS CORP. MEDIF overview

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specializing in precision-based cannabinoids, is pleased to announce it has launched the new Shake & Puff CBN THC Nighttime Inhaler in Canada. This innovative product expands MediPharm’s leading CBN oil product portfolio and builds on the success of the Company’s THC Inhaler introduced earlier this year. The new...

TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“ MediPharm ” or the “ Company ”), a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual and special meeting (the “ Meeting ”) of holders of common shares (" Shareholders ") held today. There were 146 Shareholders represented virtually or by proxy at the Meeting holding an aggregate of 210,726,733 common...

TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“ MediPharm ” or the “ Company ”), a pharmaceutical company specialized in precision-based cannabinoids, wishes to respond to a misleading press release published earlier today by Apollo Technology Capital Corporation (“ Apollo ”) prematurely claiming that it considers the results of the annual and special meeting of shareholders scheduled to take place at 3:00 p.m. today (the “...

TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“ MediPharm ” or the “ Company ”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that leading independent proxy voting and corporate governance advisory firm Glass, Lewis & Co. LLC (“ Glass Lewis ”) published a report on June 12, 2025 recommending that MediPharm shareholders vote the GREEN Proxy or voting instruction form FOR the Company’s...

TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“ MediPharm ,” the “ Company ,” “ we ” or “ us ”), a pharmaceutical company specialized in precision-based cannabinoids, today reminded its shareholders that the deadline is approaching to cast your vote for the upcoming Annual and Special Meeting of Shareholders on June 16, 2025 (the “ Meeting ”). All votes must be received no later than 3:00 p.m. (Eastern time) on Friday,...

TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“ MediPharm ” or the “ Company ”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that the Superior Court of Justice – Ontario (Commercial List) (the “ Court ”) has fully dismissed the application (CV-25-00743454-00CL) (the “ Application ”) issued by Apollo Technology Capital Corporation (“ Apollo ”) and Nobul Technologies Inc....

TORONTO, June 05, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm"), a pharmaceutical company specialized in precision-based cannabinoids, announced the closing of the sale of its Hope, British Columbia facility (the “Hope Facility”) to Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) for $4.5 million in cash (the “Transaction”). In parallel, the Company is expanding annual international cultivation capacity at its EU GMP-certified...

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“ MediPharm ” or the “ Company ”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that Institutional Shareholder Services (“ ISS ”) published a report on May 30, 2025 (the “ ISS Report ”) recommending that MediPharm shareholders vote the GREEN Proxy or voting instruction form FOR the Company’s nominees for the Board of Directors (the “...